TRPML1 is a promising target1 for Parkinson’s disease treatments and identifying translational biomarkers will help confirm target engagement in clinical studies ...
When I was diagnosed with Parkinson’s in August 2019, a doctor told me that Sinemet (Levodopa/Carbidopa), the starter drug of choice, often runs its course in 5 years, and for 50% of the people, it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results